Related Experiment Video
Updated: Aug 6, 2026
Detecting the Lyme Disease Spirochete, Borrelia Burgdorferi, in Ticks Using Nested PCR
Published on: February 4, 2018
The Lyme vaccine: a cautionary tale
Abstract:
People living in endemic areas acquire Lyme disease from the bite of an infected tick. This infection, when diagnosed and treated early in its course, usually responds well to antibiotic therapy. A minority of patients develops more serious disease, particularly after a delay in diagnosis or therapy, and sometimes chronic neurological, cardiac, or rheumatological manifestations. In 1998, the FDA approved a new recombinant Lyme vaccine, LYMErix, which reduced new infections in vaccinated adults by nearly 80%. Just 3 years later, the manufacturer voluntarily withdrew its product from the market amidst media coverage, fears of vaccine side-effects, and declining sales. This paper reviews these events in detail and focuses on the public communication of risks and benefits of the Lyme vaccine and important lessons learned.
Insights
Lyme disease is a tick-borne illness. A vaccine (LYMErix) was approved but later withdrawn due to safety concerns and low sales, offering lessons in public communication.
Area of Science:
- Infectious Diseases
- Vaccinology
- Public Health Communication
Background:
- Lyme disease is a tick-borne illness prevalent in endemic areas, treatable with antibiotics if diagnosed early.
- A recombinant Lyme vaccine (LYMErix) demonstrated high efficacy (80% reduction in infections) in vaccinated adults.
- The vaccine was voluntarily withdrawn from the market just three years after its 1998 FDA approval.
Discussion:
- The withdrawal of LYMErix was influenced by media reports, public apprehension regarding vaccine side-effects, and declining commercial sales.
- Effective risk-benefit communication is crucial for public acceptance and the success of novel medical interventions.
- Analyzing the LYMErix case provides valuable insights into managing public perception of vaccine safety and efficacy.
Key Insights:
- Public perception and media influence significantly impact the market viability of medical products, even effective ones.
- Transparent and proactive communication strategies are essential to address public concerns about vaccine safety and efficacy.
- The LYMErix experience underscores the need for robust post-market surveillance and communication plans for new vaccines.
Outlook:
- Future Lyme disease vaccine development must prioritize not only scientific efficacy but also comprehensive public engagement strategies.
- Lessons learned from LYMErix can inform the development and communication of future vaccines for tick-borne diseases.
- Strengthening public trust through clear, evidence-based communication will be vital for the successful introduction of new public health tools.
Related Concept Videos
01:51Vaccinations
01:21Vaccines
01:19Encephalitis l: Introduction
01:22Botulism
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:26Rocky Mountain Spotted Fever